Spots Global Cancer Trial Database for urothelial carcinoma
Every month we try and update this database with for urothelial carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) | NCT03898180 | Urothelial Carc... | Pembrolizumab Lenvatinib Placebo for len... | 18 Years - | Merck Sharp & Dohme LLC | |
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | NCT02989064 | Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | NCT04198766 | Solid Tumor Non-Small Cell ... Melanoma Head and Neck C... Gastric Cancer Renal Cell Carc... Urothelial Carc... | INBRX-106 - Hex... Pembrolizumab 2... Pembrolizumab 4... | 18 Years - | Inhibrx, Inc. | |
| Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer | NCT06310759 | Urothelial Carc... | 18 Years - 100 Years | Tampere University Hospital | ||
| Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma | NCT03658304 | Urothelial Carc... | Mitomycin c | 18 Years - 99 Years | University of Florida | |
| Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma | NCT03486197 | Urothelial Carc... | Laboratory Biom... Pembrolizumab Radiation Thera... | 18 Years - | University of Washington | |
| Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | NCT04383938 | Bladder Cancer Gastric Cancer Non Small Cell ... NSCLC Urothelial Carc... Advanced Solid ... | APR-246 (eprene... | 18 Years - | Aprea Therapeutics | |
| Cabozantinib for Advanced Urothelial Cancer | NCT01688999 | Urothelial Carc... Urethral Neopla... Urinary Bladder... Kidney Neoplasm... | Cabozantinib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | NCT05874921 | Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Canc... Urothelial Carc... Carcinoma, Tran... Transitional Ce... | Jelmyto (mitomy... | 18 Years - | UroGen Pharma Ltd. | |
| Efficacy and Utility of Cxbladder Tests in Hematuria Patients | NCT04943380 | Hematuria Urothelial Carc... | Cxbladder | 18 Years - | Pacific Edge Limited | |
| Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer | NCT03272217 | Urothelial Carc... | Atezolizumab Bevacizumab | 18 Years - | Hoosier Cancer Research Network | |
| Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study | NCT06339138 | Chromophobe Ren... Clear Cell Papi... Clear Cell Rena... Kidney Oncocyto... Papillary Renal... Urothelial Carc... | Non-Interventio... | 18 Years - | Mayo Clinic | |
| Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma | NCT04730219 | Muscle Invasive... Urothelial Carc... | Tislelizumab Nab paclitaxel | 18 Years - | Tianjin Medical University Second Hospital | |
| Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma | NCT01606345 | Urothelial Carc... | Valrubicin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce) | NCT03399643 | Urothelial Carc... | Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma | NCT03658304 | Urothelial Carc... | Mitomycin c | 18 Years - 99 Years | University of Florida | |
| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | NCT03829436 | Hepatocellular ... Metastatic Cast... Renal Cell Carc... Non-small Cell ... Colorectal Canc... Squamous Cell C... Triple-Negative... Urothelial Carc... Cholangiocarcin... GastroEsophagea... Pancreatic Canc... Sarcoma | Part 1 TPST-112... Part 2 TPST-112... Part 3 TPST-112... Part 4 TPST-112... | 18 Years - | Tempest Therapeutics | |
| Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | NCT03190174 | Ewing Sarcoma PEComa Epithelioid Sar... Desmoid Tumor Chordoma Non Small Cell ... Urothelial Carc... Melanoma Renal Cell Carc... Squamous Cell C... Hepatocellular ... Classical Hodgk... Colorectal Canc... MTOR Activating... | Nab-Rapamycin Nivolumab | 12 Years - | Sarcoma Oncology Research Center, LLC | |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | NCT03452774 | Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... | Clinical Trial ... | - | Massive Bio, Inc. | |
| Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | NCT02795156 | Non-small Cell ... Urothelial Carc... Gastrointestina... Upper Aerodiges... | Afatinib Regorafenib Cabozantinib | 18 Years - | SCRI Development Innovations, LLC | |
| A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors | NCT05180799 | Solid Tumor, Ad... NSCLC Urothelial Carc... Gastric Cancer Small Cell Lung... Hepatocellular ... Cervical Carcin... Melanoma Renal Cell Carc... Carcinoma | BA3071 Nivolumab Pembrolizumab | 18 Years - | BioAtla, Inc. | |
| A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer | NCT03507166 | Urothelial Carc... Advanced Cancer | RC48-ADC | 18 Years - 80 Years | RemeGen Co., Ltd. | |
| A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder | NCT05137262 | Urothelial Carc... Bladder Cancer | Abiraterone ace... Durvalumab Methotrexate Vinblastine Doxorubicin Hyd... Cisplatin | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | NCT03517488 | Melanoma Breast Carcinom... Hepatocellular ... Urothelial Carc... Squamous Cell C... Renal Cell Carc... Colorectal Carc... Non-small Cell ... Gastric or Gast... Endometrial Car... Mesothelioma Neuroendocrine ... Cervical Cancer Small Cell Lung... Squamous Cell C... Castration-Resi... Nasopharyngeal ... Cholangiocarcin... Basal Cell Carc... Ovarian Carcino... Fallopian Tube ... Thymoma Thymic Carcinom... Squamous Cell C... Vulvar Carcinom... Solid Tumors Wi... Malignant Adnex... Non-squamous Ce... | XmAb20717 | 18 Years - | Xencor, Inc. | |
| Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic | NCT04770974 | Urothelial Carc... Bladder Cancer Urothelial Neop... Urothelial Carc... Urothelial Carc... | Biomarkers and ... | 18 Years - | University of Florence | |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | NCT04140526 | Non Small Cell ... Advanced Solid ... Metastatic Mela... Metastatic Head... Metastatic Rena... Metastatic Colo... Sarcomas Metastatic Pros... Ovarian Cancer Small Cell Lung... Metastatic Brea... Pancreas Cancer Gastric Cancer Esophageal Canc... Gastroesophagea... Cervical Cancer Adenoid Cystic ... Salivary Gland ... Urothelial Carc... | ONC-392 Pembrolizumab Docetaxel | 18 Years - | OncoC4, Inc. | |
| Evolution of Proteomic Profiles of Intestinal Microbiota in Patients With Locally Advanced or Metastatic Urothelial Carcinomas | NCT04566029 | Urothelial Carc... | Blood test Stool sample Questionnaires | 18 Years - | Centre Hospitalier Universitaire de Nīmes | |
| Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | NCT05585034 | Head and Neck S... Melanoma Exclud... Non-small Cell ... Urothelial Carc... Renal Cell Carc... Castration-resi... Ovarian Cancer,... TNBC - Triple-N... Colorectal Canc... | XmAb®808 Keytruda® (pemb... | 18 Years - | Xencor, Inc. | |
| Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma | NCT01071928 | Urothelial Carc... | Docetaxel ASA404 | 18 Years - | Hoosier Cancer Research Network | |
| A Study of Personalized Neoantigen Cancer Vaccines | NCT03794128 | Non Small Cell ... Colorectal Canc... Gastroesophagea... Urothelial Carc... Pancreatic Duct... | Blood collectio... Blood collectio... | 18 Years - | Gritstone bio, Inc. | |
| Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC | NCT05768347 | Urothelial Carc... Non-Invasive Bl... | Adoptive Cell T... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | NCT03869190 | Urothelial Carc... Bladder Cancer | Atezolizumab Enfortumab Vedo... Niraparib Magrolimab (Hu5... Tiragolumab Sacituzumab Gov... Tocilizumab Cisplatin Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma | NCT00588666 | Myeloproliferat... Urothelial Carc... Cancer | Bevacizumab Carboplatin Gemcitabine | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC | NCT05200988 | Urothelial Carc... Bladder Cancer | Ipilimumab + ni... | 18 Years - | The Netherlands Cancer Institute | |
| Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies. | NCT06321640 | Breast Cancer Lung Cancer Melanoma Head and Neck C... Urothelial Carc... Colorectal Canc... Liver Metastase... Lung Metastases | Cohort A: prima... Cohort B: local... Cohort C: metas... Cohort D: Progr... Cohort E: Hemat... Cohort F: Toxic... | 18 Years - | European Institute of Oncology | |
| Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC | NCT04543110 | Bladder Cancer | Durvalumab Immune Modulati... | 18 Years - | Ottawa Hospital Research Institute | |
| B7-Family Score in Urothelial Carcinoma | NCT06169904 | Urothelial Carc... | Cisplatin injec... | - | Shanghai Zhongshan Hospital | |
| Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | NCT01366144 | Breast Carcinom... Carcinoma of Un... Endometrial Car... Esophageal Carc... Liver Failure Lung Carcinoma Malignant Head ... Malignant Testi... Melanoma Metastatic Mali... Ovarian Carcino... Renal Failure Unresectable Ma... Urothelial Carc... | Carboplatin Laboratory Biom... Paclitaxel Pharmacological... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer | NCT04553939 | Urothelial Carc... Bladder Cancer | Toripalimab Gemcitabine | 18 Years - 75 Years | Henan Cancer Hospital | |
| Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation | NCT05912205 | Urothelial Carc... | Disitamab Vedot... radiotherapy | 18 Years - | Wuhan Union Hospital, China | |
| A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | NCT03970382 | Solid Tumor | NeoTCR-P1 adopt... nivolumab IL-2 | 18 Years - | PACT Pharma, Inc. | |
| Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects | NCT02365766 | Urothelial Carc... Bladder Cancer | Pembrolizumab Gemcitabine Cisplatin Consolidative S... | 18 Years - | Hoosier Cancer Research Network | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | NCT05581004 | Locally Advance... NSCLC HNSCC Melanoma TNBC Esophageal Canc... Gastric Cancer Cervical Cancer Urothelial Carc... Clear Cell RCC HCC | RO7502175 Atezolizumab | 18 Years - | Genentech, Inc. | |
| A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer | NCT02426125 | Urothelial Carc... | Ramucirumab Docetaxel Placebo | 18 Years - | Eli Lilly and Company | |
| Efficacy and Utility of Cxbladder Tests in Hematuria Patients | NCT04943380 | Hematuria Urothelial Carc... | Cxbladder | 18 Years - | Pacific Edge Limited | |
| Multimodal Spectroscopy to Detect Urothelial Cancer in Urine | NCT04718948 | Urothelial Carc... Urinary Bladder... Urinary Tract C... | Urinary Multimo... Urine Cytology Surgery | 18 Years - | University of Florence | |
| Urine DNA Methylation Detection for Hematuria Evaluation | NCT06427993 | Hematuria Urothelial Carc... Bladder Cancer Ureter Cancer Renal Pelvis Ca... | 18 Years - 99 Years | Changhai Hospital | ||
| TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma | NCT04678362 | Urothelial Carc... | Talazoparib + A... | 18 Years - | Centre Francois Baclesse | |
| Improve Checkpoint-blockade Response in Advanced Urothelial Cancer | NCT03871036 | Urothelial Carc... | Tremelimumab Durvalumab Paclitaxel | 18 Years - | The Netherlands Cancer Institute | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | NCT03212404 | Lung Neoplasms Carcinoma, Non-... Carcinoma, Smal... Malignant Mesot... Head and Neck C... Melanoma Merkel Cell Car... Renal Cell Carc... Urothelial Carc... Classical Hodgk... Cutaneous Squam... Non Hodgkin Lym... Endometrial Can... | CK-301 (cosibel... | 18 Years - | Checkpoint Therapeutics, Inc. | |
| A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer | NCT04073602 | Urothelial Carc... | RC48-ADC | 18 Years - 80 Years | RemeGen Co., Ltd. | |
| A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | NCT06405425 | Urothelial Carc... | BL-B01D1 PD-1 | 18 Years - 75 Years | Sichuan Baili Pharmaceutical Co., Ltd. | |
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | NCT04106167 | Advanced Solid ... Lymphoma Gastric Cancer Colorectal Canc... Head and Neck C... Squamous Cell C... EGFR Positive S... HER2-positive B... Hepatocellular ... Small-cell Lung... Renal Cell Carc... Pancreas Cancer Melanoma NSCLC Urothelial Carc... Cervical Cancer Microsatellite ... Merkel Cell Car... | Allogeneic natu... | 18 Years - | Fate Therapeutics | |
| Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy | NCT05574504 | Metastatic Canc... Urothelial Carc... | avelumab (PD-L1... | 18 Years - | AdventHealth | |
| Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma | NCT02807636 | Urothelial Carc... | Atezolizumab Carboplatin Gemcitabine Placebo Cisplatin | 18 Years - | Hoffmann-La Roche | |
| A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | NCT06405425 | Urothelial Carc... | BL-B01D1 PD-1 | 18 Years - 75 Years | Sichuan Baili Pharmaceutical Co., Ltd. | |
| Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers | NCT04459273 | Bladder Carcino... Cervical Carcin... Cholangiocarcin... Hematopoietic a... Hepatocellular ... Malignant Adren... Malignant Brain... Malignant Pleur... Malignant Skin ... Malignant Solid... Malignant Testi... Malignant Thymu... Neuroendocrine ... Thyroid Gland C... Urothelial Carc... Cancer of Unkno... | Computed Tomogr... Gallium Ga 68 F... Positron Emissi... 18F-FDG | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Memory-like Natural Killer (NK) Cell Therapy With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma | NCT06318871 | Renal Carcinoma Renal Cell Carc... Urothelial Carc... | Cytokine Induce... N-803 | 18 Years - | Dana-Farber Cancer Institute | |
| A Prospective, Multi-centre, Single-blinded Study of UroCAD for Urothelial Carcinoma Diagnosis and Follow-up | NCT04432909 | Urothelial Carc... | The level of CN... | 18 Years - | Changhai Hospital | |
| A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China | NCT05337189 | Bladder Cancer Urocystitis Urinary Bladder... Urothelial Carc... | Urine DNA methy... medical imaging... | - | Creative Biosciences (Guangzhou) Co., Ltd. | |
| Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients | NCT03924466 | Metastatic Brea... Locally Advance... Cancer of Pancr... Solid Tumor Wit... Salivary Gland ... Gastric Cancer Endometrial Can... Uterine Cancer Non Small Cell ... Biliary Tract C... Cholangiocarcin... Colorectal Canc... Urothelial Carc... Prostate Cancer | 68GaNOTA-Anti-H... | 18 Years - | Universitair Ziekenhuis Brussel | |
| GEN1046 Safety Trial in Patients With Malignant Solid Tumors | NCT03917381 | Solid Tumors Non-small Cell ... Urothelial Carc... Endometrial Car... Triple Negative... Squamous Cell C... Cervical Cancer | Acasunlimab Acasunlimab in ... Acasunlimab in ... Acasunlimab in ... | 18 Years - | Genmab | |
| Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma | NCT02807636 | Urothelial Carc... | Atezolizumab Carboplatin Gemcitabine Placebo Cisplatin | 18 Years - | Hoffmann-La Roche | |
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | NCT05243550 | Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-102 | 18 Years - | UroGen Pharma Ltd. | |
| Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients | NCT03924466 | Metastatic Brea... Locally Advance... Cancer of Pancr... Solid Tumor Wit... Salivary Gland ... Gastric Cancer Endometrial Can... Uterine Cancer Non Small Cell ... Biliary Tract C... Cholangiocarcin... Colorectal Canc... Urothelial Carc... Prostate Cancer | 68GaNOTA-Anti-H... | 18 Years - | Universitair Ziekenhuis Brussel | |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | NCT04260802 | Cancer Neoplasms Metastatic Canc... Triple Negative... Gastric Cancer Cervical Cancer Ovarian Cancer Hepatocellular ... Squamous Cell C... Urothelial Carc... Urothelial Neop... Non Small Cell ... Renal Cell Carc... Locally Advance... Locally Advance... Squamous Cell C... Sarcoma Merkel Cell Car... Bladder Cancer | OC-001 OC-001 in Combi... | 18 Years - | Ocellaris Pharma, Inc. | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract | NCT04617756 | Urothelial Carc... Cancer | Patients receiv... | 18 Years - | Centre Hospitalier Universitaire de Nīmes | |
| Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma. | NCT04066595 | Urothelial Carc... | Cabozantinib | 18 Years - | Johannes Gutenberg University Mainz | |
| Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma | NCT05030077 | Urothelial Carc... Anlotinib Urogenital Neop... Cisplatin Carboplatin Gemcitabine Antineoplastic ... | Anlotinib Cisplatin Carboplatin Gemcitabine | 18 Years - 75 Years | Tianjin Medical University Second Hospital | |
| EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells | NCT01993966 | Urothelial Carc... | 20 Years - 80 Years | National Taiwan University Hospital | ||
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | NCT02769962 | Urothelial Carc... Urothelial Canc... Lung Neoplasms Small Cell Lung... Prostate Cancer | EP0057 olaparib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy | NCT01437488 | Urothelial Carc... | Cabazitaxel Neulasta CT Scan Blood Draw | 18 Years - | Thomas Jefferson University | |
| Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy | NCT03208712 | Urothelial Carc... | Atezolizumab Radium-223 | 18 Years - | University of Michigan Rogel Cancer Center | |
| Value of Cortactin Expression in Invasive and Non-invasive Urinary Bladder Urothelial Carcinoma in Egyptian Population | NCT05070039 | Urothelial Carc... | Expression of C... | - | Sohag University | |
| ARON-2 Study-Multicentric International Retrospective Study | NCT05290038 | Urothelial Carc... | 18 Years - | Hospital of Macerata | ||
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | NCT02573259 | Part 1 MELANOMA SCCHN OVCA SARCOMA OTHER SOLID TUM... Part 1 and 2 NSCLC UROTHELIAL CARC... | PF-06801591 PF-06801591 | 18 Years - | Pfizer | |
| Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma | NCT03179943 | Urothelial Carc... | Atezolizumab Guadecitabine | 18 Years - | Fox Chase Cancer Center | |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | NCT03126110 | Advanced Malign... Metastatic Canc... | INCAGN01876 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
